Cardiovascular risk factors and chronic kidney disease - FGF23: A key molecule in the cardiovascular disease

International Journal of Hypertension

Volumn 2014, Issue , 2014, Pages

  Jimbo, Rika ^a   Shimosawa, Tatsuo ^b  

^a Odaira Memorial Tokyo Hitachi Hospital   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; KLOTHO PROTEIN;

BLOOD VESSEL CALCIFICATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMPLEX FORMATION; DISEASE ASSOCIATION; FEEDBACK SYSTEM; GENE EXPRESSION REGULATION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT;

EID: 84896728556     PISSN: 20900384     EISSN: 20900392     Source Type: Journal    
DOI: 10.1155/2014/381082     Document Type: Review

References (101)

1. Go A. S., Chertow G. M., Fan D., McCulloch C. E., Hsu C.-Y., Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. The New England Journal of Medicine 2004 351 13 1296 1370 2-s2.0-4644221457 10.1056/NEJMoa041031 (Pubitemid 39268908)
2. Ninomiya T., Kiyohara Y., Kubo M., Tanizaki Y., Doi Y., Okubo K., Wakugawa Y., Hata J., Oishi Y., Shikata K., Yonemoto K., Hirakata H., Iida M., Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama study. Kidney International 2005 68 1 228 236 2-s2.0-24944475735 10.1111/j.1523-1755.2005.00397.x (Pubitemid 43181380)
3. Foley R. N., Parfrey P. S., Sarnak M. J., Clinical epidemiology of cardiovascular disease in chronic renal disease. American Journal of Kidney Diseases 1998 32 5, supplement 3 S112 S119 2-s2.0-0031733696 (Pubitemid 28527268)
4. Herzog C. A., Ma J. Z., Collins A. J., Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. The New England Journal of Medicine 1998 339 12 799 805 2-s2.0-0032541672 10.1056/NEJM199809173391203 (Pubitemid 28447453)
5. Wanner C., Krane V., März W., Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. The New England Journal of Medicine 2005 353 3 238 248 10.1056/NEJMoa043545 (Pubitemid 41058323)
6. Moe S., Drüeke T., Cunningham J., Goodman W., Martin K., Olgaard K., Ott S., Sprague S., Lameire N., Eknoyan G., Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International 2006 69 11 1945 1953 2-s2.0-33645757920 10.1038/sj.ki.5000414 (Pubitemid 43924257)
7. Moe S. M., Drüeke T. B., Block G. A., KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney International 2009 113 S1 S130
8. Bhuriya R., Li S., Chen S.-C., McCullough P. A., Bakris G. L., Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP). American Journal of Kidney Diseases 2009 53 4, supplement 4 S3 S10 2-s2.0-61749084092 10.1053/j.ajkd.2008.11.029
9. Kimata N., Albert J. M., Akiba T., Yamazaki S., Kawaguchi T., Fukuhara S., Akizawa T., Saito A., Asano Y., Kurokawa K., Pisoni R. L., Port F. K., Association of mineral metabolism factors with all-cause and cardiovascular mortality in hemodialysis patients: the Japan Dialysis Outcomes and Practice Patterns Study (J-DOPPS). Hemodialysis International 2007 11 3 340 348 (Pubitemid 46958589)
10. Wolf M., Thadhani R., Vitamin D in patients with renal failure: a summary of observational mortality studies and steps moving forward. Journal of Steroid Biochemistry and Molecular Biology 2007 103 3-5 487 490 2-s2.0-33947120203 10.1016/j.jsbmb.2006.11.009 (Pubitemid 46401279)
11. Evenepoel P., Meijers B., Viaene L., Bammens B., Claes K., Kuypers D., Vanderschueren D., Vanrenterghem Y., Fibroblast growth factor-23 in early chronic kidney disease: additional support in favor of a phosphate-centric paradigm for the pathogenesis of secondary hyperparathyroidism. Clinical Journal of the American Society of Nephrology 2010 5 7 1268 1276 2-s2.0-77954783380 10.2215/CJN.08241109
12. Isakova T., Wahl P., Vargas G. S., Gutiérrez O. M., Scialla J., Xie H., Appleby D., Nessel L., Bellovich K., Chen J., Hamm L., Gadegbeku C., Horwitz E., Townsend R. R., Anderson C. A. M., Lash J. P., Hsu C.-Y., Leonard M. B., Wolf M., Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney International 2011 79 12 1370 1378 2-s2.0-79957870135 10.1038/ki.2011.47
13. ADHR Consortium, Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nature Genetics 2000 26 3 345 348 10.1038/81664
14. Shimada T., Mizutani S., Muto T., Yoneya T., Hino R., Takeda S., Takeuchi Y., Fujita T., Fukumoto S., Yamashita T., Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proceedings of the National Academy of Sciences of the United States of America 2001 98 11 6500 6505 2-s2.0-14344279878 10.1073/pnas.101545198 (Pubitemid 32488266)
15. Larsson T., Marsell R., Schipani E., Ohlsson C., Ljunggren Ö., Tenenhouse H. S., Jüppner H., Jonsson K. B., Transgenic mice expressing fibroblast growth factor 23 under the control of the α 1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology 2004 145 7 3087 3094 2-s2.0-3042634460 10.1210/en.2003-1768 (Pubitemid 38829975)
16. Gattineni J., Bates C., Twombley K., Dwarakanath V., Robinson M. L., Goetz R., Mohammadi M., Baum M., FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. American Journal of Physiology: Renal Physiology 2009 297 2 F282 F291 2-s2.0-68049085792 10.1152/ajprenal.90742.2008
17. Dailey L., Ambrosetti D., Mansukhani A., Basilico C., Mechanisms underlying differential responses to FGF signaling. Cytokine and Growth Factor Reviews 2005 16 2 233 247 2-s2.0-18144415072 10.1016/j.cytogfr.2005.01.007 (Pubitemid 40616120)
18. Eswarakumar V. P., Lax I., Schlessinger J., Cellular signaling by fibroblast growth factor receptors. Cytokine and Growth Factor Reviews 2005 16 2 139 149 2-s2.0-18144383021 10.1016/j.cytogfr.2005.01.001 (Pubitemid 40616112)
19. Yu X., Ibrahimi O. A., Goetz R., Zhang F., Davis S. I., Garringer H. J., Linhardt R. J., Ornitz D. M., Mohammadi M., White K. E., Analysis of the biochemical mechanisms for the endocrine actions of fibroblast growth factor-23. Endocrinology 2005 146 11 4647 4656 2-s2.0-26844564690 10.1210/en.2005-0670 (Pubitemid 41446602)
20. Li H., Martin A., David V., Quarles L. D., Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. American Journal of Physiology: Endocrinology and Metabolism 2011 300 3 E508 E517 2-s2.0-79952161016 10.1152/ajpendo.00499.2010
21. Ben-Dov I. Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro-o M., Mohammadi M., Sirkis R., Naveh-Many T., Silver J., The parathyroid is a target organ for FGF23 in rats. Journal of Clinical Investigation 2007 117 12 4003 4008 2-s2.0-36849017126 10.1172/JCI32409 (Pubitemid 350224109)
22. Yamazaki M., Ozono K., Okada T., Tachikawa K., Kondou H., Ohata Y., Michigami T., Both FGF23 and extracellular phosphate activate Raf/MEK/ERK pathway via FGF receptors in HEK293 cells. Journal of Cellular Biochemistry 2010 111 5 1210 1221 2-s2.0-78649862227 10.1002/jcb.22842
23. Urakawa I., Yamazaki Y., Shimada T., Iijima K., Hasegawa H., Okawa K., Fujita T., Fukumoto S., Yamashita T., Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 2006 444 7120 770 774 2-s2.0-33845631059 10.1038/nature05315 (Pubitemid 44949607)
24. Hu M. C., Shi M., Zhang J., Pastor J., Nakatani T., Lanske B., Razzaque M. S., Rosenblatt K. P., Baum M. G., Kuro-o M., Moe O. W., Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB Journal 2010 24 9 3438 3450 2-s2.0-77956642900 10.1096/fj.10-154765
25. Kuro-O M., Phosphate and Klotho. Kidney International 2011 121 S20 S23 2-s2.0-79958743766
26. Shimada T., Urakawa I., Yamazaki Y., Hasegawa H., Hino R., Yoneya T., Takeuchi Y., Fujita T., Fukumoto S., Yamashita T., FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochemical and Biophysical Research Communications 2004 314 2 409 414 2-s2.0-9144248333 10.1016/j.bbrc.2003.12.102 (Pubitemid 38084732)
27. +/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes to Cells 2005 10 5 489 502 2-s2.0-17844392596 10.1111/j.1365-2443.2005.00853.x (Pubitemid 40590366)
28. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., Fujita T., Nakahara K., Fukumoto S., Yamashita T., FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. Journal of Bone and Mineral Research 2004 19 3 429 435 2-s2.0-2142746439 10.1359/JBMR.0301264 (Pubitemid 38787398)
29. Hasegawa H., Nagano N., Urakawa I., Yamazaki Y., Iijima K., Fujita T., Yamashita T., Fukumoto S., Shimada T., Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney International 2010 78 10 975 980 2-s2.0-78049463249 10.1038/ki.2010.313
30. Liu S., Tang W., Zhou J., Stubbs J. R., Luo Q., Pi M., Quarles L. D., Fibroblast growth factor 23 is a counter-regulatory phosphaturic hormone for vitamin D. Journal of the American Society of Nephrology 2006 17 5 1305 1315 2-s2.0-33646367420 10.1681/ASN.2005111185 (Pubitemid 43673410)
31. Masuyama R., Stockmans I., Torrekens S., van Looveren R., Maes C., Carmeliet P., Bouillon R., Carmeliet G., Vitamin D receptor in chondrocytes promotes osteoclastogenesis and regulates FGF23 production in osteoblasts. Journal of Clinical Investigation 2006 116 12 3150 3159 2-s2.0-33845296928 10.1172/JCI29463 (Pubitemid 44878629)
32. Shimada T., Yamazaki Y., Takahashi M., Hasegawa H., Urakawa I., Oshima T., Ono K., Kakitani M., Tomizuka K., Fujita T., Fukumoto S., Yamashita T., Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism. American Journal of Physiology: Renal Physiology 2005 289 5 F1088 F1095 2-s2.0-26844568409 10.1152/ajprenal.00474.2004 (Pubitemid 41447065)
33. Nishi H., Nii-Kono T., Nakanishi S., Yamazaki Y., Yamashita T., Fukumoto S., Ikeda K., Fujimori A., Fukagawa M., Intravenous calcitriol therapy increases serum concentrations of fibroblast growth factor-23 in dialysis patients with secondary hyperparathyroidism. Nephron 2005 101 2 c94 c99 2-s2.0-23944486382 10.1159/000086347 (Pubitemid 41208897)
34. Hansen D., Rasmussen K., Pedersen S. M., Rasmussen L. M., Brandi L., Changes in fibroblast growth factor 23 during treatment of secondary hyperparathyroidism with alfacalcidol or paricalcitol. Nephrology Dialysis Transplantation 2012 27 6 2263 2269 10.1093/ndt/gfr668
35. Komaba H., Fukagawa M., FGF23-parathyroid interaction: implications in chronic kidney disease. Kidney International 2010 77 4 292 298 2-s2.0-75749129364 10.1038/ki.2009.466
36. Krajisnik T., Björklund P., Marsell R., Ljunggren Ö., Åkerström G., Jonsson K. B., Westin G., Larsson T. E., Fibroblast growth factor-23 regulates parathyroid hormone and 1 α -hydroxylase expression in cultured bovine parathyroid cells. Journal of Endocrinology 2007 195 1 125 131 2-s2.0-35848947037 10.1677/JOE-07-0267 (Pubitemid 350056006)
37. Hofman-Bang J., Martuseviciene G., Santini M. A., Olgaard K., Lewin E., Increased parathyroid expression of klotho in uremic rats. Kidney International 2010 78 11 1119 1127 2-s2.0-78349310932 10.1038/ki.2010.215
38. Canalejo R., Canalejo A., Martinez-Moreno J. M., Rodriguez-Ortiz M. E., Estepa J. C., Mendoza F. J., Munoz-Castaneda J. R., Shalhoub V., Almaden Y., Rodriguez M., FGF23 fails to inhibit uremic parathyroid glands. Journal of the American Society of Nephrology 2010 21 7 1125 1135 2-s2.0-77954567520 10.1681/ASN.2009040427
39. Saji F., Shigematsu T., Sakaguchi T., Ohya M., Orita H., Maeda Y., Ooura M., Mima T., Negi S., Fibroblast growth factor 23 production in bone is directly regulated by 1 α25-dihydroxyvitamin D, but not PTH. American Journal of Physiology: Renal Physiology 2010 299 5 F1212 F1217 2-s2.0-78349288025 10.1152/ajprenal.00169.2010
40. López I., Rodríguez-Ortiz M. E., Almadén Y., Direct and indirect effects of parathyroid hormone on circulating levels of fibroblast growth factor 23 in vivo. Kidney International 2011 80 5 475 482 10.1038/ki.2011.107
41. Rhee Y., Bivi N., Farrow E., Lezcano V., Plotkin L. I., White K. E., Bellido T., Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 2011 49 4 636 643 2-s2.0-80052303008 10.1016/j.bone.2011.06.025
42. Burnett-Bowie S.-A. M., Henao M. P., Dere M. E., Lee H., Leder B. Z., Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. Journal of Bone and Mineral Research 2009 24 10 1681 1685 2-s2.0-70349934206 10.1359/jbmr.090406
43. Gutiérrez O. M., Smith K. T., Barchi-Chung A., Patel N. M., Isakova T., Wolf M., (1-34) parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers. Clinical Journal of the American Society of Nephrology 2012 7 1 139 145 2-s2.0-84857073015 10.2215/CJN.06240611
44. Wesseling-Perry K., Harkins G. C., Wang H.-J., Elashoff R., Gales B., Horwitz M. J., Stewart A. F., Jüppner H., Salusky I. B., The calcemic response to continuous parathyroid hormone (PTH)(1-34) infusion in end-stage kidney disease varies according to bone turnover: a potential role for PTH(7-84). Journal of Clinical Endocrinology and Metabolism 2010 95 6 2772 2780 2-s2.0-77954500243 10.1210/jc.2009-1909
45. Gutiérrez O. M., Mannstadt M., Isakova T., Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. The New England Journal of Medicine 2008 359 6 584 592 10.1056/NEJMoa0706130
46. Seiler S., Reichart B., Roth D., Seibert E., Fliser D., Heine G. H., FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrology Dialysis Transplantation 2010 25 12 3983 3989 2-s2.0-77956159370 10.1093/ndt/gfq309
47. Kendrick J., Cheung A. K., Kaufman J. S., Greene T., Roberts W. L., Smits G., Chonchol M., Jamison R. L., Hartigan P., Kaufman J., Goldfarb D. S., Warren S. R., Guarino P. D., Gaziano J. M., FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis. Journal of the American Society of Nephrology 2011 22 10 1913 1922 2-s2.0-80053517709 10.1681/ASN.2010121224
48. Koh N., Fujimori T., Nishiguchi S., Tamori A., Shiomi S., Nakatani T., Sugimura K., Kishimoto T., Kinoshita S., Kuroki T., Nabeshima Y.-I., Severely reduced production of klotho in human chronic renal failure kidney. Biochemical and Biophysical Research Communications 2001 280 4 1015 1020 2-s2.0-0034810211 10.1006/bbrc.2000.4226 (Pubitemid 32924441)
49. Jean G., Terrat J.-C., Vanel T., Hurot J.-M., Lorriaux C., Mayor B., Chazot C., High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrology Dialysis Transplantation 2009 24 9 2792 2796 2-s2.0-69249106380 10.1093/ndt/gfp191
50. Olauson H., Qureshi A. R., Miyamoto T., Barany P., Heimburger O., Lindholm B., Stenvinkel P., Larsson T. E., Relation between serum fibroblast growth factor-23 level and mortality in incident dialysis patients: are gender and cardiovascular disease confounding the relationship? Nephrology Dialysis Transplantation 2010 25 9 3033 3038 2-s2.0-77956245971 10.1093/ndt/gfq191
51. Isakova T., Xie H., Yang W., Xie D., Anderson A. H., Scialla J., Wahl P., Gutiérrez O. M., Steigerwalt S., He J., Schwartz S., Lo J., Ojo A., Sondheimer J., Hsu C.-Y., Lash J., Leonard M., Kusek J. W., Feldman H. I., Wolf M., Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. Journal of the American Medical Association 2011 305 23 2432 2439 2-s2.0-79958724181 10.1001/jama.2011.826
52. Nakano C., Hamano T., Fujii N., Obi Y., Matsui I., Tomida K., Mikami S., Inoue K., Shimomura A., Nagasawa Y., Okada N., Tsubakihara Y., Rakugi H., Isaka Y., Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis. Bone 2012 50 6 1266 1274 2-s2.0-84858714318 10.1016/j.bone.2012.02.634
53. Hsu H. J., Wu M.-S., Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. American Journal of the Medical Sciences 2009 337 2 116 122 2-s2.0-61849155234 10.1097/MAJ. 0b013e3181815498
54. Gutiérrez O. M., Januzzi J. L., Isakova T., Laliberte K., Smith K., Collerone G., Sarwar A., Hoffmann U., Coglianese E., Christenson R., Wang T. J., DeFilippi C., Wolf M., Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009 119 19 2545 2552 2-s2.0-66349097180 10.1161/CIRCULATIONAHA.108.844506
55. Kirkpantur A., Balci M., Gurbuz O. A., Afsar B., Canbakan B., Akdemir R., Ayli M. D., Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrology Dialysis Transplantation 2011 26 4 1346 1354 2-s2.0-79953880208 10.1093/ndt/gfq539
56. Faul C., Amaral A. P., Oskouei B., Hu M.-C., Sloan A., Isakova T., Gutiérrez O. M., Aguillon-Prada R., Lincoln J., Hare J. M., Mundel P., Morales A., Scialla J., Fischer M., Soliman E. Z., Chen J., Go A. S., Rosas S. E., Nessel L., Townsend R. R., Feldman H. I., Sutton M. S. J., Ojo A., Gadegbeku C., di Marco G. S., Reuter S., Kentrup D., Tiemann K., Brand M., Hill J. A., Moe O. W., Kuro-o M., Kusek J. W., Keane M. G., Wolf M., FGF23 induces left ventricular hypertrophy. Journal of Clinical Investigation 2011 121 11 4393 4408 2-s2.0-80555148939 10.1172/JCI46122
57. Shalhoub V., Shatzen E. M., Ward S. C., FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. Journal of Clinical Investigation 2012 122 7 2543 2553 10.1172/JCI61405
58. London G. M., Guérin A. P., Marchais S. J., Métivier F., Pannier B., Adda H., Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrology Dialysis Transplantation 2003 18 9 1731 1740 2-s2.0-0042885985 10.1093/ndt/gfg414 (Pubitemid 37098542)
59. Shanahan C. M., Crouthamel M. H., Kapustin A., Giachelli C. M., Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circulation Research 2011 109 6 697 711 2-s2.0-80052561697 10.1161/CIRCRESAHA. 110.234914
60. Hruska K., Mathew S., Lund R., Fang Y., Sugatani T., Cardiovascular risk factors in chronic kidney disease: does phosphate qualify? Kidney international 2011 79 supplement 121 S9 S13 10.1038/ki.2011.24 2-s2.0-79958721700
61. Jono S., McKee M. D., Murry C. E., Shioi A., Nishizawa Y., Mori K., Morii H., Giachelli C. M., Phosphate regulation of vascular smooth muscle cell calcification. Circulation Research 2000 87 7 E10 E17 2-s2.0-0034730291
62. Li X., Yang H.-Y., Giachelli C. M., Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circulation Research 2006 98 7 905 912 2-s2.0-33646157733 10.1161/01.RES. 0000216409.20863.e7
63. Speer M. Y., Yang H.-Y., Brabb T., Leaf E., Look A., Lin W.-L., Frutkin A., Dichek D., Giachelli C. M., Smooth muscle cells give rise to osteochondrogenic precursors and chondrocytes in calcifying arteries. Circulation Research 2009 104 6 733 741 2-s2.0-64249157371 10.1161/CIRCRESAHA. 108.183053
64. Goodman W. G., Goldin J., Kuizon B. D., Yoon C., Gales B., Sider D., Wang Y., Chung J., Emerick A., Greaser L., Elashoff R. M., Salusky I. B., Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. The New England Journal of Medicine 2000 342 20 1478 1483 2-s2.0-0034682247 10.1056/NEJM200005183422003 (Pubitemid 30318271)
65. Adeney K. L., Siscovick D. S., Ix J. H., Seliger S. L., Shlipak M. G., Jenny N. S., Kestenbaum B. R., Association of serum phosphate with vascular and valvular calcification in moderate CKD. Journal of the American Society of Nephrology 2009 20 2 381 387 2-s2.0-59949102335 10.1681/ASN.2008040349
66. Ix J. H., de Boer I. H., Peralta C. A., Adeney K. L., Duprez D. A., Jenny N. S., Siscovick D. S., Kestenbaum B. R., Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clinical Journal of the American Society of Nephrology 2009 4 3 609 615 2-s2.0-66149157312 10.2215/CJN.04100808
67. Villa-Bellosta R., Bogaert Y. E., Levi M., Sorribas V., Characterization of phosphate transport in rat vascular smooth muscle cells: implications for vascular calcification. Arteriosclerosis, Thrombosis, and Vascular Biology 2007 27 5 1030 1036 2-s2.0-34247339631 10.1161/ATVBAHA.106.132266 (Pubitemid 46641988)
68. Taylor J., Butcher M., Zeadin M., Politano A., Shaughnessy S. G., Oxidized low-density lipoprotein promotes osteoblast differentiation in primary cultures of vascular smooth muscle cells by up-regulating Osterix expression in an Msx2-dependent manner. Journal of Cellular Biochemistry 2011 112 2 581 588 2-s2.0-79251630740 10.1002/jcb.22948
69. Mitani H., Ishizaka N., Aizawa T., Ohno M., Usui S.-I., Suzuki T., Amaki T., Mori I., Nakamura Y., Sato M., Nangaku M., Hirata Y., Nagai R., In vivo Klotho gene transfer ameliorates angiotensin II-induced renal damage. Hypertension 2002 39 4 838 843 2-s2.0-0036235099 10.1161/01.HYP.0000013734. 33441.EA (Pubitemid 34437536)
70. Nakano-Kurimoto R., Ikeda K., Uraoka M., Nakagawa Y., Yutaka K., Koide M., Takahashi T., Matoba S., Yamada H., Okigaki M., Matsubara H., Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. American Journal of Physiology: Heart and Circulatory Physiology 2009 297 5 H1673 H1684 2-s2.0-70350438009 10.1152/ajpheart.00455.2009
71. Donate-Correa J., Mora-Fernández C., Martínez-Sanz R., Expression of FGF23/KLOTHO system in human vascular tissue. International Journal of Cardiology 2013 165 1 179 183 10.1016/j.ijcard.2011.08.850
72. Lim K., Lu T. S., Molostvov G., Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation 2012 125 18 2243 2255 10.1161/CIRCULATIONAHA.111.053405
73. Scialla J. J., Lau W. L., Reilly M. P., Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney International 2013 83 6 1159 1168 10.1038/ki.2013.3
74. Lindberg K., Olauson H., Amin R., Ponnusamy A., Goetz R., Taylor R. F., Mohammadi M., Canfield A., Kublickiene K., Larsson T. E., Arterial klotho expression and FGF23 effects on vascular calcification and function. PLoS ONE 2013 8 4 e60658 10.1371/journal.pone.0060658
75. Fang Y., Ginsberg C., Sugatani T., Monier-Faugere M. C., Malluche H., Hruska K. A., Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney International 2013 10.1038/ki.2013.271
76. Jimbo R., Kawakami-Mori F., Mu S., Fibroblast growth factor 23 accelerates phosphate-induced vascular calcification in the absence of Klotho deficiency. Kidney International 2013 10.1038/ki.2013.332
77. Nakayama M., Kaizu Y., Nagata M., Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrology 2013 14, article 22 10.1186/1471-2369-14-22
78. Balci M., Kirkpantur A., Gulbay M., Gurbuz O. A., Plasma fibroblast growth factor-23 levels are independently associated with carotid artery atherosclerosis in maintenance hemodialysis patients. Hemodialysis International 2010 14 4 425 432 2-s2.0-77958572969 10.1111/j.1542-4758.2010.00480.x
79. Nasrallah M. M., El-Shehaby A. R., Salem M. M., Osman N. A., El Sheikh E., Sharaf El Din U. A., Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrology Dialysis Transplantation 2010 25 8 2679 2685 2-s2.0-77954090037 10.1093/ndt/gfq089
80. Burnett S.-A. M., Gunawardene S. C., Bringhurst F. R., Jüppner H., Lee H., Finkelstein J. S., Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. Journal of Bone and Mineral Research 2006 21 8 1187 1196 2-s2.0-33746406756 10.1359/jbmr.060507 (Pubitemid 44128331)
81. Ferrari S. L., Bonjour J.-P., Rizzoli R., Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. Journal of Clinical Endocrinology and Metabolism 2005 90 3 1519 1524 2-s2.0-15944376583 10.1210/jc.2004-1039 (Pubitemid 40464013)
82. Isakova T., Gutirrez O. M., Smith K., Epstein M., Keating L. K., Jppner H., Wolf M., Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrology Dialysis Transplantation 2011 26 2 584 591 2-s2.0-79551500014 10.1093/ndt/gfq419
83. Isakova T., Barchi-Chung A., Enfield G., Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD. Clinical Journal of the American Society of Nephrology 2013 8 6 1009 1018 10.2215/CJN.09250912
84. Cancela A. L. E., Oliveira R. B., Graciolli F. G., Dos Reis L. M., Barreto F., Barreto D. V., Cuppari L., Jorgetti V., Carvalho A. B., Canziani M. E., Moysés R. M. A., Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate. Nephron 2010 117 1 c74 c82 2-s2.0-77955110868 10.1159/000319650
85. Koiwa F., Kazama J. J., Tokumoto A., Onoda N., Kato H., Okada T., Nii-Kono T., Fukagawa M., Shigematsu T., Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Therapeutic Apheresis and Dialysis 2005 9 4 336 339 2-s2.0-29144475911 (Pubitemid 41800805)
86. Oliveira R. B., Cancela A. L. E., Graciolli F. G., Dos Reis L. M., Draibe S. A., Cuppari L., Carvalho A. B., Jorgetti V., Canziani M. E., Moysés R. M. A., Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clinical Journal of the American Society of Nephrology 2010 5 2 286 291 2-s2.0-77749334660 10.2215/CJN.05420709
87. Chue C. D., Townend J. N., Moody W. E., Cardiovascular effects of sevelamer in stage 3 CKD. Journal of the American Society of Nephrology 2013 24 5 842 852 10.1681/ASN.2012070719
88. Gonzalez-Parra E., Gonzalez-Casaus M. L., Galán A., Martinez-Calero A., Navas V., Rodriguez M., Ortiz A., Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrology Dialysis Transplantation 2011 26 8 2567 2571 2-s2.0-79961052017 10.1093/ndt/gfr144
89. Soriano S., Ojeda R., Rodríguez M., The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients. Clinical Nephrology 2013 80 1 17 22 10.5414/CN107764
90. Koizumi M., Komaba H., Nakanishi S., Fujimori A., Fukagawa M., Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism. Nephrology Dialysis Transplantation 2012 27 2 784 790 2-s2.0-81255194004 10.1093/ndt/gfr384
91. Wetmore J. B., Liu S., Krebill R., Menard R., Quarles L. D., Effects of cinacalcet and concurrent low-dose vitamin D on FGF23 levels in ESRD. Clinical Journal of the American Society of Nephrology 2010 5 1 110 116 2-s2.0-75749131627 10.2215/CJN.03630509
92. Kim H. J., Kim H., Shin N., Cinacalcet lowering of serum fibroblast growth factor-23 concentration may be independent from serum Ca, P, PTH and dose of active vitamin D in peritoneal dialysis patients: a randomized controlled study. BMC Nephrology 2013 14, article 112 10.1186/1471-2369-14-112
93. Finch J. L., Tokumoto M., Nakamura H., Yao W., Shahnazari M., Lane N., Slatopolsky E., Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease. American Journal of Physiology: Renal Physiology 2010 298 6 F1315 F1322 2-s2.0-77952718903 10.1152/ajprenal.00552.2009
94. Wesseling-Perry K., Pereira R. C., Sahney S., Gales B., Wang H.-J., Elashoff R., Jüppner H., Salusky I. B., Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney International 2011 79 1 112 119 2-s2.0-78650265254 10.1038/ki.2010.352
95. Teng M., Wolf M., Ofsthun M. N., Lazarus J. M., Hernán M. A., Camargo C. A. Jr., Thadhani R., Activated injectable vitamin D and hemodialysis survival: a historical cohort study. Journal of the American Society of Nephrology 2005 16 4 1115 1125 2-s2.0-20844459261 10.1681/ASN.2004070573 (Pubitemid 41710323)
96. Naves-Díaz M., Alvarez-Hernández D., Passlick-Deetjen J., Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney International 2008 74 8 1070 1078 10.1038/ki.2008.343
97. Zebger-Gong H., Müller D., Diercke M., Haffner D., Hocher B., Verberckmoes S., Schmidt S., D'Haese P. C., Querfeld U., 1,25-dihydroxyvitamin D3-induced aortic calcifications in experimental uremia: up-regulation of osteoblast markers, calcium-transporting proteins and osterix. Journal of Hypertension 2011 29 2 339 348 2-s2.0-78651342326 10.1097/HJH.0b013e328340aa30
98. Drüeke T. B., Role of vitamin D in vascular calcification: bad guy or good guy? Nephrology Dialysis Transplantation 2012 27 5 1704 1707 10.1093/ndt/gfs046
99. Aoshima Y., Mizobuchi M., Ogata H., Vitamin D receptor activators inhibit vascular smooth muscle cell mineralization induced by phosphate and TNF- α Nephrology Dialysis Transplantation 27 5 1800 1806
100. Bodyak N., Ayus J. C., Achinger S., Shivalingappa V., Ke Q., Chen Y.-S., Rigor D. L., Stillman I., Tamez H., Kroeger P. E., Wu-Wong R. R., Karumanchi S. A., Thadhani R., Kang P. M., Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proceedings of the National Academy of Sciences of the United States of America 2007 104 43 16810 16815 2-s2.0-36749043736 10.1073/pnas.0611202104 (Pubitemid 350210947)
101. Thadhani R., Appelbaum E., Pritchett Y., Chang Y., Wenger J., Tamez H., Bhan I., Agarwal R., Zoccali C., Wanner C., Lloyd-Jones D., Cannata J., Thompson B. T., Andress D., Zhang W., Packham D., Singh B., Zehnder D., Shah A., Pachika A., Manning W. J., Solomon S. D., Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. Journal of the American Medical Association 2012 307 7 674 684 2-s2.0-84857079741 10.1001/jama.2012.120